Managing Skin Ageing as a Modifiable Disorder—The Clinical Application of Nourella® Dual Approach Comprising a Nano-Encapsulated Retinoid, Retilex-A® and a Skin Proteoglycan Replacement Therapy, Vercilex®

Skin ageing is a progressive, but modifiable, multi-factorial disorder that involves all the skin’s tissues. Due to its wide range of physiological and psychosocial complications, skin requires rigorous clinical attention. In this review, we aim encourage clinicians consider as suggest novel, dual approach treatment. Topical retinoids per-oral proteoglycans are promising, non-invasive, therapeutic modalities. To overcome low bioavailability conventional free retinoids, Nourella® cream with Retilex-A® (Pharma Medico, Aarhus, Denmark) was developed using proprietary nano-encapsulation technology. The sophisticated ‘permeation/penetration enhancer’ optimises topical drug delivery by increasing surface availability net absorption ratio. Treatment adherence also improved minimising irritation. Interventional evidence suggests greater efficacy in improving thickness elasticity compared forms. It reported rejuvenating tretinoin comparable. Another anti-ageing proteoglycan replacement therapy (PRT) Vercilex®. Vercilex® tablet form has potential ameliorate dysmetabolism aged activating cells collagen/elastin turnover. Replicated trials evidenced PRT can significantly enhance density, both intrinsically photoaged skin. Evidently, share bioactivities underlie their synergistic activity, observed trial. Dual tablets produced effects on characteristics than monotherapy each two treatments. conclusion, safe effective treatments for ageing; however, combining ‘dual rejuvenation system’ improves treatment outcomes.